Fujisawa Prograf Ad Fails To Sufficiently Disclose Risks, FDA Warning Letter Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company’s response will include a plan of action to provide appropriate risk information. Fujisawa did not submit the journal ad for agency review at the time of its dissemination.
You may also be interested in...
Prograf Ads Mislead On CV, Nephrotoxicity Risk – DDMAC
Warning letter to Astellas is not the first time FDA has cited Prograf ads for downplaying risks.
Prograf Ads Mislead On CV, Nephrotoxicity Risk – DDMAC
Warning letter to Astellas is not the first time FDA has cited Prograf ads for downplaying risks.
Astellas' Prograf Wins FDA Okay For Heart Transplant Indication
Company is awaiting FDA approval of ads before launching the new indication for the immunosuppressant tacrolimus in May.